Infectious and Rare Diseases
Overview of the global human respiratory syncytial virus drugs market
The global human respiratory syncytial virus (RSV) drugs market is anticipated to grow at a steady rate and post a CAGR of more than 4% during the forecast period. The increasing usage of novel diagnostic tools will drive the growth prospects for the global human respiratory syncytial virus drugs market until the end of 2020. Novel diagnostic tools are used to detect, screen, and evaluate individuals with respiratory syncytial virus (RSV). Some of the novel diagnostic methods include rapid diagnostic assays, RT-PCR assays, and serological tests. Also, the vendors and researchers are increasingly focusing on the development of novel diagnostic tests due to the rising demand for accurate diagnosis. For instance, Quidel offers the Lyra RSV + hMPV assay for the qualitative detection and identification of RSV. Such diagnostic tools deliver results equivalent to central laboratory standards within 70 minutes and are more effective and accurate. Other such products include Idylla Respiratory IFV-RSV Panel for the detection of various strains of RSV and influenza virus.
The active participation of emerging economies toward research and development will drive the growth prospects for the market during the forecast period. The increasing R&D activities in emerging economies for RSV infection and its causes will fuel the development of novel drugs. One of the major factors responsible for the market’s growth is the rising amount of patented therapies for RSV treatment that result in substantial R&D activities from various big pharma companies and research institutes. For instance, in June 2016, the Lancet Respiratory Medicine reported that RSV was the most commonly detected pathogen linked with pneumonia among children in South Africa. Such new findings will increase the scope of anti-RSV drugs in new applications, such as
Overview of the global alopecia drugs market
The global alopecia drugs market is anticipated to grow at a steady rate and will post a CAGR of more than 5% during the forecast period. The increasing popularity of off-label and over-the-counter (OTC) drugs will drive the growth prospects for the global alopecia drugs market during the forecast period. Off-label drugs are used extensively by the consumers because the exact therapy targeted at remission of alopecia is currently unavailable. For instance, AVODART is approved for the treatment of prostate cancer, but this drug is also used for the treatment of alopecia. Such drugs are used in the absence of any proven remission track and can be a threat to the market’s growth in the future. However, at present, the increasing use of off-label drugs is fuelling the sale of these drugs. Also, these drugs are being used for unapproved clinical indication or extension to a milder form of approved indication or extension to related conditions. For instance, alopecia market heavily uses spironolactone and cyclosporine, which are primarily approved for other indications.
In terms of geography, the Americas accounted for the maximum market share in 2015 because the US was the largest revenue contributor in the region. During the forecast period, the Americas will continue to dominate the market due to the increasing awareness about the disease and drugs in the region. Furthermore, the changing lifestyle of individuals is resulting in hormonal imbalances due to increased stress, consumption of junk food, and physical inactivity. Also, the increasing rate of hormonal imbalances in the region can cause disorders that will increase the consumption of drugs.
Competitive landscape and key vendors
The leading vendors of the market are investing extensively in R&D of new drugs because there are no effective treatment options available for
Outlook of the gout therapeutics market
The global market for gout therapeutics will grow at a CAGR of over 17% by 2020. A major factor leading to the steady growth of this market is the growing focus on regenerative medicines. The utilization of regenerative medicines for the treatment of gout is an emerging treatment option for healthcare professionals. These medications aid in the overall healing process by replacement or regeneration of the human cells, tissues, or organs and help in establishing normal body functions. The various regenerative techniques include cell therapy and growth factor therapy. Various companies engaged in the development of regenerative medicines for the treatment of gout are MEDIPOST, TETEC, ISTO Technologies, Histogenics, Vericel, Omeros Corporation, and Cerapedics.
According to the analysts at Technavio, eminent trends, such as the high growth potential of biologics, will also help in the growth of this market during the forecast period. Biologics have a high affinity towards specific disease cells and account for over 18% of the global pharmaceutical sales. They will continue to outperform pharmaceuticals in terms of product sales, as there is an increasing need for effective treatment options. Biologics that treat gout are generally made from proteins. They work by blocking the action of the main chemicals or cells involved in the inflammation of joints. Few of the biologicals used to treat gout include Canakinumab, Krystexxa, and Rilonacept.
Competitive landscape and key vendors
At present, the global out therapeutics market is growing at a rapid pace owing to the increased demand for gout drugs. This recent increase in the demand for effective drugs is leading to an increase in R&D spend. Vendors that exhibit a high efficacy and safety profile in
Overview of the animal antibacterial and antibiotics market
According to the market research analysts at Technavio, the global animal antibacterial and antibiotics market is anticipated to witness steady growth and will post a moderate CAGR of more than 5% over the forecast period. A sharp rise in pet ownership has led to a significant rise in demand for animal health products such as antibacterial and antibiotics. Such animal health products are intended to enhance the quality of life of these animals. The increasing recognition of pets as family members has diverted the focus toward better health care services for them. Also, the participation of animals in sports also necessitates regular care for these animals to ensure optimal performance. Furthermore, with the advancements in veterinary therapeutics and preventive medicines, along with an increase in disposable income is expected to boost the demand for better care for pets and livestock.
One of the recent trends spurring this market’s growth is the increasing collaborations between academic institutions and leading companies in the market to develop novel products for animal healthcare. For example, in 2013, The Roslin Institute at the University of Edinburgh and Zoetis collaborated to jointly investigate the entry route, mechanism of persistence in cattle, and beef contamination by Salmonella. Such collaborations enable the incorporation of research expertise of academic institutions with the marketing intelligence of pharma companies, contributing to the market’s growth
Overview of hemophilia drugs market
Extensive research carried out by the analysts at Technavio has shown that the global hemophilia drugs market will witness steady growth and will post a moderate CAGR of more than 5% over the forecast period. With increasing focus on prophylactic treatment, the market for hemophilia drugs is expected to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth.
In terms of geography, the Americas led the global hemophilia drugs market in 2015 and is expected to continue its dominance until the end of 2020. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on the market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on healthcare insurance and also
Overview of the methicillin-resistant Staphylococcus aureus (MRSA) drugs market
Methicillin-resistant Staphylococcus aureus (MRSA) is a skin infection that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and is highly contagious. This infection is difficult to treat because it is sometimes resistant to commonly-used antibiotics such as methicillin. As per this market research report, the aging people are highly susceptible to MRSA infections, especially in the hospital environment as their weak immune system makes them easily prone to diseases and infections. The early detection of these diseases and growing awareness of their treatment drugs will positively aid to the growth of this market in the coming years. Technavio’s market research analyst predicts the global MRSA drugs market to grow at a steady CAGR of around 1% by 2020.
The surge in the number of infections and infectious diseases is creating unmet needs in the market. This has propelled government-based and non-governmental institutes to take up initiatives to develop antibiotics by providing the necessary funding to the research institutes and companies. Several nations across the globe are actively providing funds to develop antibacterial drugs and fight antibacterial drug resistance and its surveillance. Such funding encourages research institutes and companies to invest more in antibiotic research, thereby resulting in the growth of this market.
Segmentation by drug class and analysis of the MRSA drugs market
- Folate antagonist
Tetracyclines prevent bacterial protein synthesis by reversibly binding to the bacterial 30S ribosomes. They act against Gram-positive and Gram-negative bacteria; however, most of the
The market for treatments for infectious, rare, and orphan diseases is booming, and will continue to do so through the forecast period. The anti-infectives therapeutic segment has the most potential, as it has multiple first-in-class innovations, especially for emerging infectious diseases.
Additionally, the advent of novel therapeutics has revolutionized the treatment paradigm for some infectious diseases. The industry is focused on increasing pharmaceutical research and development activities to innovate and develop new products that can improve patient outcomes. This will continue to be the prime driver for this diversified therapeutic segment.
Despite the target population being smaller, drugs approved for orphan diseases remain revenue boosters for pharmaceutical companies. Key factors fueling the interest of pharmaceutical companies in including orphan drugs in their product portfolios include premium drug prices, high unmet need, extended market exclusivities, tax grants, and reduced timeframes for clinical development.